Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLQ | O75417 | 1/20 | 0.38 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.35 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.31 |
| ▸ | PTGES | O14684 | 3/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | MLYCD | O95822 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30266971 | 0.94 | GPBAR1 (0.35) | POLQKCNK3KCNK9GPBAR1MEN1 | |
| SCHEMBL23716797 | 0.94 | GPBAR1 (0.35) | POLQKCNK3KCNK9GPBAR1MEN1 | |
| SCHEMBL24914497 | 0.92 | POLQ (0.38) | POLQKCNK3KCNK9MEN1LMNA | |
| SCHEMBL21563473 | 0.91 | GPBAR1 (0.38) | POLQKCNK3KCNK9GPBAR1MAPT | |
| SCHEMBL23716450 | 0.90 | GPBAR1 (0.33) | POLQGPBAR1RXFP1MLYCD | |
| SCHEMBL21563800 | 0.90 | GPBAR1 (0.34) | POLQKCNK3KCNK9GPBAR1MEN1 | |
| SCHEMBL23059630 | 0.89 | GPBAR1 (0.33) | POLQGPBAR1PTGES | |
| SCHEMBL31679336 | 0.89 | TSHR (0.38) | KCNK3KCNK9MEN1LMNAMAPT | |
| SCHEMBL23716929 | 0.89 | SMN1; SMN2 (0.36) | POLQGPBAR1MEN1LMNAMAPT | |
| SCHEMBL28621340 | 0.89 | TSHR (0.38) | KCNK3KCNK9MEN1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238126-A1 | Benzamide Compound and Use Thereof | METISA BIOTECHNOLOGY CO.,LTD. (CN) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238126-A1 | Benzamide Compound and Use Thereof | TMBIM6, BCHE, DDT | POLQ 4771/4885KCNK3 1286/4885KCNK9 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.